<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Quality Risk Management — How Much Evidence Is Enough on Temple Quality in Pharma Course</title><link>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/</link><description>Recent content in Quality Risk Management — How Much Evidence Is Enough on Temple Quality in Pharma Course</description><generator>Hugo</generator><language>en</language><lastBuildDate>Sat, 12 Sep 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/index.xml" rel="self" type="application/rss+xml"/><item><title>FMEA in Detail — Scoring, Scaling, and Where It Breaks</title><link>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/</link><pubDate>Sat, 12 Sep 2026 00:00:00 +0000</pubDate><guid>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/</guid><description>&lt;picture&gt;&lt;source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_20b8474734fd7b5c.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_41ef425267e04aca.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_4c0192daa30117f6.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_e547299a4293f97a.avif 1600w" sizes="100vw"&gt;&lt;source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_a78ead6acaa8e92a.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_b4c8035f2ef6242a.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_4f0340b99efff9f6.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_fe59397d74faf24f.webp 1600w" sizes="100vw"&gt;&lt;img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_f1c4f65901f4412e.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_ea78600f0ad83f17.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_f1c4f65901f4412e.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_b7de52a6bc2a5b9.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/1-fmea/image_hu_48695f88abe0176f.png 1600w" sizes="100vw" alt="A banner titled &amp;#39;FMEA in Detail — Scoring, Scaling, and Where It Breaks&amp;#39; with the tagline &amp;#39;Find the important failures. Take the right action. Don&amp;#39;t over-trust the number.&amp;#39; and the note that this is a worked example from an HPLC assay method, with practical guidance for real decisions. Panels: (1) The One Idea — RPN is a prioritization tool, not a measurement; it tells you which failure mode to look at first, not how much worse one is than another, and treating it like it does is the single most common way an FMEA goes wrong, with the note to focus effort where it matters for the patient and avoid gold-plating the rest; (2) How FMEA Works — a five-step chevron: list the process steps (e.g., sample prep, separation, detection, data analysis, reporting), identify failure modes (what could fail at each step), analyze effects and causes (what would it do, why would it happen, how would we catch it), score S, O, D (Severity, Occurrence, Detection), take action and re-score (implement risk controls and re-score to show the improvement) — captioned as a living tool, updated when methods, instruments, materials, or knowledge change; (3) The RPN Formula — RPN = S × O × D, with Severity (how bad the effect is on the patient or the decision, 1 = negligible to 10 = catastrophic e.g. potential patient harm), Occurrence (how often it is expected to happen, 1 = remote to 10 = very high frequency), and Detection (how likely current controls are to catch it before it matters, with the callout that a high score means poorly detected because the scale runs backward — 1 = almost certain to detect, 10 = very unlikely to detect); (4) Typical 1–10 Scales (Examples) — a table mapping score bands (10, 5, 1) to example Severity, Occurrence, and Detection descriptions, with a note to use defined, documented criteria tailored to the method, product, and patient risk; (5) Worked Example — HPLC Assay Method FMEA, a five-row table (mis-integrated peak, wrong diluent used, column-to-column carryover, drifting calibration curve, co-eluting unknown degradant) each with process step/failure mode, effect, cause, current control, S, O, D, RPN, a risk control action, and a re-scored RPN, with the note that carryover (RPN 200) outranks drifting calibration (RPN 108) even though a wrong release decision from drifting calibration may seem worse — because detection was poor (D = 8) — RPN doing its job of surfacing the blind spot, not just the scariest-sounding failure; (6) Why the Same RPN Can Mean Very Different Things — two failure modes (A: rare but severe, S=9 O=2 D=5; B: more frequent, less severe, S=5 O=3 D=6) both scoring RPN 90, with the point that a severity-first reviewer would act on A first regardless of the tied RPN, which is exactly why you shouldn&amp;#39;t rank by RPN alone and why any mode with severity ≥ 9 should be automatically flagged for action; (7) Known Limitations — RPN is an ordinal product, not a true measurement (100 is not twice as bad as 50); detection and occurrence are often guesses, and Q9(R1) highlights this subjectivity, asking for defined scales, cross-functional input, and documented assumptions; different (S,O,D) combinations can give the same RPN with very different meaning; it can miss low-probability, high-severity events (use severity-first rules); it is not a substitute for scientific judgment — it&amp;#39;s a tool to structure it; (8) FMEA vs. FMECA — a side-by-side comparison: FMEA uses S×O×D (RPN), prioritizes failure modes, is simple and widely used, good for method development; FMECA adds criticality analysis (e.g., a severity/probability matrix), often includes failure-mode ratios, is better for high-risk or regulated products, and most analytical FMEAs are effectively FMECAs in practice; (9) When to Use Other Risk Tools — a table of five tools (fault tree analysis for working backward from a failure, useful for OOS root-cause investigation; HACCP for identifying and controlling critical points, useful in manufacturing or sample handling; HAZOP for deviations from design intent, useful in process/engineering systems; risk ranking and filtering for comparing many unrelated risks, useful for site or portfolio decisions; Ishikawa/fishbone/PHA for first-pass hazard identification, useful for early method or process review); (10) From Risk to Control Strategy — a five-step numbered flow: identify CQAs (attribute risk assessment), assess method parameters (method FMEA), implement controls (e.g., robustness, system suitability), set specifications (Q6) and stability program (Q1), monitor and manage change (Q14), with the note that a control strategy is the output of risk management, not a separate exercise; (11) Worked Case — Nitrosamine Risk Assessment, a bulleted walkthrough: identify hazard (potent mutagenic carcinogens, e.g. NDMA, NDEA, drug-specific), analyze risk (synthetic route, nitrite sources, secondary amines, recovered solvents), control risk (route changes, nitrite scavengers, tighter limits at ppb levels), communicate (to the agency, on a deadline), analytical challenge (need methods sensitive enough to detect at the acceptable intake). Footer: &amp;#39;Science &amp;#43; Risk-Based Thinking = Better Medicines for Patients,&amp;#39; Temple University branding, and the tagline &amp;#39;All science ultimately serves people.&amp;#39;" class="" loading="lazy" decoding="async" /&gt;
 &lt;/picture&gt;
&lt;h2 id="the-one-idea"&gt;The one idea&lt;/h2&gt;
&lt;blockquote&gt;
&lt;p&gt;RPN is a prioritization tool, not a measurement. It tells you which failure mode to look at first — it does not tell you how much worse one failure mode is than another, and treating it like it does is the single most common way an FMEA goes wrong.&lt;/p&gt;</description></item><item><title>Fault Tree Analysis — Working Backward From a Failure</title><link>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/2-fault-tree-analysis/</link><pubDate>Sat, 12 Sep 2026 00:00:00 +0000</pubDate><guid>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/2-fault-tree-analysis/</guid><description>&lt;h2 id="the-one-idea"&gt;The one idea&lt;/h2&gt;
&lt;blockquote&gt;
&lt;p&gt;FMEA asks, before anything has gone wrong, &amp;ldquo;what could fail in this process?&amp;rdquo; FTA asks, after something already has, &amp;ldquo;what chain of causes could have produced exactly this failure?&amp;rdquo; They run in opposite directions through the same failure space, and a mature quality system uses both.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h2 id="mechanics"&gt;Mechanics&lt;/h2&gt;
&lt;p&gt;A fault tree starts with a single, precisely defined &lt;strong&gt;top event&lt;/strong&gt; — the failure that occurred — and branches downward through &lt;strong&gt;logic gates&lt;/strong&gt; to the conditions that could produce it:&lt;/p&gt;</description></item><item><title>HACCP — Critical Control Points, Borrowed From Food Safety</title><link>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/3-haccp/</link><pubDate>Sat, 12 Sep 2026 00:00:00 +0000</pubDate><guid>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/3-haccp/</guid><description>&lt;h2 id="the-one-idea"&gt;The one idea&lt;/h2&gt;
&lt;blockquote&gt;
&lt;p&gt;Instead of scoring every failure mode in a process, HACCP asks a narrower, sharper question: where in this process is a &lt;strong&gt;critical control point&lt;/strong&gt; — a step where losing control means the hazard reaches the patient, with nothing downstream left to catch it?&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h2 id="mechanics"&gt;Mechanics&lt;/h2&gt;
&lt;p&gt;HACCP originated in food safety (developed for NASA&amp;rsquo;s manned space program, to guarantee astronaut food had zero tolerance for contamination) and maps cleanly onto sterile and biologic manufacturing, which share that same &amp;ldquo;no downstream catch&amp;rdquo; property. The full method has seven principles; the ones that matter for a control-strategy discussion are:&lt;/p&gt;</description></item><item><title>HAZOP — Deviations From Design Intent</title><link>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/4-hazop/</link><pubDate>Sat, 12 Sep 2026 00:00:00 +0000</pubDate><guid>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/4-hazop/</guid><description>&lt;h2 id="the-one-idea"&gt;The one idea&lt;/h2&gt;
&lt;blockquote&gt;
&lt;p&gt;HAZOP doesn&amp;rsquo;t start from a list of known failure modes the way FMEA does — it starts from the process&amp;rsquo;s own &lt;strong&gt;design intent&lt;/strong&gt; and systematically asks what happens if reality deviates from it, one guide word at a time, parameter by parameter.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h2 id="mechanics"&gt;Mechanics&lt;/h2&gt;
&lt;p&gt;For each parameter at each step of a process (flow rate, temperature, pressure, pH, concentration, time), a HAZOP team applies a fixed set of &lt;strong&gt;guide words&lt;/strong&gt; and asks what a deviation of that kind would actually cause:&lt;/p&gt;</description></item><item><title>Risk Ranking and Filtering — Comparing Risks That Don't Share a Scale</title><link>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/5-risk-ranking-and-filtering/</link><pubDate>Sat, 12 Sep 2026 00:00:00 +0000</pubDate><guid>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/5-risk-ranking-and-filtering/</guid><description>&lt;h2 id="the-one-idea"&gt;The one idea&lt;/h2&gt;
&lt;blockquote&gt;
&lt;p&gt;FMEA scores risks &lt;em&gt;within&lt;/em&gt; one process on one shared scale. Risk ranking and filtering compares risks &lt;em&gt;across&lt;/em&gt; processes, products, or sites that have no natural shared scale at all, by explicitly defining and weighting the criteria that make one risk matter more than another.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h2 id="mechanics"&gt;Mechanics&lt;/h2&gt;
&lt;ol&gt;
&lt;li&gt;&lt;strong&gt;Define criteria&lt;/strong&gt; that matter across every risk being compared — typically patient impact, regulatory exposure, likelihood, and detectability, though a portfolio-level exercise might add business impact or timeline pressure.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Weight the criteria&lt;/strong&gt; to reflect what actually matters most in this decision (patient impact usually carries the most weight; timeline pressure usually carries the least, if it&amp;rsquo;s included at all).&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Score each risk against every criterion&lt;/strong&gt;, using whatever scale is practical (often 1–5, sometimes qualitative bands converted to numbers).&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Compute a weighted score and rank&lt;/strong&gt; — then &lt;strong&gt;filter&lt;/strong&gt;: set a threshold or a headcount/budget cutoff and act on what clears it, explicitly documenting why anything below the line is being deferred.&lt;/li&gt;
&lt;/ol&gt;
&lt;p&gt;The &amp;ldquo;filtering&amp;rdquo; half is as important as the ranking half — the exercise exists to produce a short, defensible action list, not just a long sorted table nobody acts on.&lt;/p&gt;</description></item><item><title>Ishikawa / Fishbone / PHA — Structuring the First Pass</title><link>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/6-ishikawa-fishbone-pha/</link><pubDate>Sat, 12 Sep 2026 00:00:00 +0000</pubDate><guid>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/2-sep21/2-risk-management/6-ishikawa-fishbone-pha/</guid><description>&lt;h2 id="the-one-idea"&gt;The one idea&lt;/h2&gt;
&lt;blockquote&gt;
&lt;p&gt;An FMEA is only as complete as its failure-mode list, and that list has to come from somewhere. Ishikawa (fishbone) diagrams and Preliminary Hazard Analysis are how you brainstorm it systematically, category by category, instead of relying on whoever&amp;rsquo;s in the room to remember everything from experience.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;h2 id="mechanics"&gt;Mechanics&lt;/h2&gt;
&lt;p&gt;An Ishikawa diagram starts from a defined &lt;strong&gt;effect&lt;/strong&gt; (an observed or feared problem) and branches into standard categories of contributing cause. Adapted for an analytical lab, the categories are usually:&lt;/p&gt;</description></item></channel></rss>